6,678 trials
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation — 30.7 percentage of participants
Toothache
Primary: Percentage of Participants With a Response — 70.4; 80.7; 87.3 Percentage of participants — p=<0.001
Glabellar Lines
Primary: Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial…
Rheumatoid Arthritis · Psoriatic Arthritis · Psoriasis
Primary: Baseline (Wk 0) Disease Activity Score (DAS28) — 4.54; 6.03 Score
Esophageal Diseases · Gastrointestinal Diseases · Disorder of the Genitourinary System
Primary: Length of Hospital Stay (LOS) by Participant
Major Depressive Disorder
Primary: Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-week Treatment Period — -1.93; -1.31 units on a scale — p=<0.001
Glaucoma · Ocular Hypertension
Primary: Mean Diurnal Intraocular Pressure (IOP) at Week 12 — 15.4; 19.2 Millimeters of mercury (mm Hg)
Hypertension
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy — -18.2; -12.3 mm Hg
Anemia · Chronic Kidney Disease
Primary: Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event — 27; 25; 26 participants
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in HbA1c at Week 24 — -0.47; -0.38 Percent (%) — p=0.26
Hypotrichosis
Primary: Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 — 69.6; 48.8 Percentage of Patients
Pompe Disease (Late-Onset) · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis Type II
Primary: Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600) — 60; 37; 21…
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.857; -0.871 percentage (%) of total haemoglobin
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Lung Function as Measured by the Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0-3h (AUC0-3h) — -0.06; 0.16 litres *…